8-K: Merit Medical Systems Launches Wrapsody CIE in the US, Eyes $7M-$9M Revenue in 2025

Merit Medical Systems initiates the U.S. commercial launch of its WRAPSODY Cell-Impermeable Endoprosthesis (CIE) following FDA premarket approval, projecting $7 million to $9 million in revenue for 2025.

Summary

• Merit Medical Systems has launched the WRAPSODY Cell-Impermeable Endoprosthesis (CIE) in the U.S. after receiving FDA premarket approval.
• The company anticipates generating between $7 million and $9 million in revenue from U.S. sales of the Wrapsody CIE in 2025.
• The Wrapsody CIE is designed to address stenosis in dialysis outflow circuits and prevent tissue growth through the graft.
• Merit is pursuing add-on reimbursement for the Wrapsody CIE in both hospital and office-based settings, with decisions expected in June 2025.
• The company's commercial strategy includes targeted engagement with new and existing customers, physician training events, and securing approvals from group purchasing organizations and integrated delivery networks.
• Merit's Renal Therapies Group is leveraging its existing portfolio of dialysis products to drive adoption of the Wrapsody CIE.
• The company believes the Wrapsody CIE offers a compelling opportunity to improve patient outcomes and reduce healthcare costs.
• Merit has invested in organic and inorganic opportunities to broaden its therapeutic platform and strengthen its commercial position in the dialysis market.
• The company has studied 423 patients in the U.S. and international markets in its WRAPSODY FIRST and WRAPSODY WAVE STUDY clinical trials, demonstrating safety and significantly stronger efficacy versus the standard of care.
• Merit intends to enroll up to 500 patients in a post-market study, currently underway, called, WRAP OUS GLOBAL REGISTRY and will be initiating a new post-market study of up to 250 patients in the U.S. and Canada, called WRAP North America Registry, in June of this year.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for Merit Medical Systems with the launch of the Wrapsody CIE and projected revenue growth. The company has a clear strategy for commercialization and reimbursement, and clinical data supports the device's safety and efficacy. However, there are some risks and uncertainties associated with reimbursement and competition.

Positives

• FDA premarket approval for the WRAPSODY Cell-Impermeable Endoprosthesis (CIE).
• Strong clinical data supporting the safety and efficacy of the Wrapsody CIE.
• Potential for add-on reimbursement payments (NTAP and TPT) in hospital and office-based settings.
• Experienced Renal Therapies Group with a comprehensive commercial strategy.
• Targeted plan to engage with new and existing customers and build physician advocacy.
• Premium pricing strategy aligned with long-term reimbursement goals.
• Novel product design with unique features to improve patient outcomes.
• Broad portfolio of dialysis products to leverage for cross-selling opportunities.
• The company has studied 423 patients in the U.S. and international markets in its WRAPSODY FIRST and WRAPSODY WAVE STUDY clinical trials, demonstrating safety and significantly stronger efficacy versus the standard of care.
• Merit intends to enroll up to 500 patients in a post-market study, currently underway, called, WRAP OUS GLOBAL REGISTRY and will be initiating a new post-market study of up to 250 patients in the U.S. and Canada, called WRAP North America Registry, in June of this year.

Negatives

• Uncertainty regarding the outcome of NTAP and TPT add-on reimbursement applications.
• Potential competitive impact from disclosing commercial strategy details.
• Pricing of the device compared to competitors may strongly influence outpatient adoption.
• Larger diameter sheaths necessary to use the Wrapsody, compared to its competitors.
• Absence of clinical use in treatment across the elbow joints.

Risks

• Failure to secure NTAP and TPT add-on reimbursement payments could impact revenue projections.
• Competition from existing covered stent grafts in the market.
• Slower than expected adoption of the Wrapsody CIE due to VAC approval processes or physician preferences.
• Pricing pressures in the outpatient setting.
• Potential for adverse events or complications associated with the device.
• The clinical advantages in routine practices of the cell-impermeable membrane are still unknown in routine clinical practice.

Future Outlook

Merit Medical Systems expects a steady stream of progress in reimbursement, clinical validation, and awareness of the Wrapsody CIE throughout 2025, with a larger weighting of revenue in the second half of the year due to anticipated add-on reimbursement payments.

Management Comments

• Fred Lampropoulos: 'Wrapsody CIE should not be viewed as the culmination, but rather, more likely represents the first of what we believe will be a series of outcomes of this multi-year strategic initiative.'
• John Hall: 'Clinical results like those reported in these pivotal trials, reflect changes in patient lives, period. Less time in the chair, less time and risk from reinterventions and an overall improvement in quality of life for patients.'
• Caleb Konstanski: 'We believe the Wrapsody CIE offers a compelling opportunity to not only improve patient outcomes, but also to reduce the cost of treating this patient population.'

Industry Context

The dialysis access maintenance market is a significant area of unmet clinical need, with a large patient population undergoing frequent procedures to maintain access patency. Merit Medical Systems is positioning the Wrapsody CIE as a premium product that can improve patient outcomes and reduce healthcare costs compared to existing covered stents and angioplasty procedures. Competitors in this space include companies offering covered stents, drug-coated balloons, and thrombectomy devices.

Comparison to Industry Standards

• The Wrapsody CIE's 84.6% target lesion primary patency at 12 months in the WRAPSODY FIRST study compares favorably to historical patency rates for covered stents in dialysis access circuits.
• The device's cell-impermeable membrane is a key differentiator compared to existing covered stents, which may allow tissue ingrowth and restenosis.
• The company's focus on securing add-on reimbursement payments aligns with industry trends to support the adoption of innovative medical technologies.
• The company's plan to host physician training events at Centers of Excellence is a common practice in the medical device industry to drive product adoption and utilization.

Stakeholder Impact

• Shareholders: Potential for increased revenue and profitability.
• Employees: Opportunity to work on a novel medical device with the potential to improve patient outcomes.
• Customers (Physicians): Access to a new treatment option for dialysis access maintenance.
• Patients: Potential for improved patency rates and reduced reinterventions.
• Payers: Potential for reduced healthcare costs due to fewer reinterventions.

Next Steps

• Continue pursuing NTAP and TPT add-on reimbursement payments.
• Execute commercial strategy to drive adoption of the Wrapsody CIE.
• Host physician training events at Centers of Excellence.
• Present clinical data at medical meetings and publish in peer-reviewed journals.
• Monitor competitive landscape and adjust strategy as needed.
• Enroll patients in post-market studies to further validate the safety and efficacy of the Wrapsody CIE.

Key Dates